AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 15 - (NewsRx.com & NewsRx.net) -- Research shows for the first time that decreases in bone turnover during the initial period of three to six months of osteoporosis treatment explains part of the rapid decrease in vertebral fracture risk seen with risedronate (Actonel/Optinate).
This may provide physicians with an important and simple tool to rapidly assess response to osteoporosis therapy. Until now, the primary way for physicians to monitor osteoporosis treatment response was measurement of bone mineral density (BMD) after one or two years, which left physicians and patients uncertain about treatment response during this period. In addition, BMD increases explain only about 20% of the fracture reduction seen with current therapies.
Bone resorption markers offer a meaningful alternative to measure early treatment response, according to data presented at the American Society of Bone and Mineral Research (ASBMR) 23rd Annual Meeting in Phoenix, Arizona, USA. Data were presented by Richard Eastell, MD FRCP FMedSci, professor of bone metabolism and director of the division of clinical sciences (North), University of Sheffield, U.K., from an analysis of 2,442 women who participated in two risedronate fracture trials. The analysis demonstrated that decreases in bone turnover measured three to six months after initiating treatment explain about 50% of risedronate's one year effect against vertebral fractures, and about 66% of risedronate's vertebral fracture risk reduction over three years.
"These findings mark the first time we can establish a connection between decreases in bone resorption markers and decreases in fracture risk. The data show the potential value of bone resorption markers as a simple assessment tool to measure treatment response," said Eastell. "Risedronate was shown to ...